Replimune Prices $150M Offering at $12.06/Share — 3 Days After FDA Approval
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune priced a $150 million public offering at $12.06 per share, a premium to its last close, just three days after FDA approval of TUDRIQEV. The raise funds the commercial launch and extends cash runway, but dilutes existing shareholders by approximately 13%.
Key Events · Financing and Capital Events · REPL
-
$150M Offering Priced at Premium
Replimune is selling 9,701,490 common shares at $12.06 and pre-funded warrants for 2,736,340 shares at $12.0599, raising $150 million in gross proceeds. The price is a slight premium to the August 7 close of $12.06, reflecting strong demand.
-
Net Proceeds of ~$140.5M
After underwriting discounts and expenses, Replimune will receive approximately $140.5 million. The funds are earmarked for the commercial launch of TUDRIQEV, pipeline expansion, and working capital.
-
Immediate Dilution of ~13%
The offering adds 12.4 million shares (including pre-funded warrant shares) to the 82.7 million outstanding as of March 31, 2026, resulting in dilution of about 13% for existing shareholders.
-
Strategic Timing Post-FDA Approval
The raise comes three days after FDA accelerated approval of TUDRIQEV for advanced melanoma. The company previously had a going concern warning and cash only into Q1 2027; this financing significantly extends the runway.
Analysis · REPL · Life Sciences
Just three days after securing FDA accelerated approval for its first commercial product, TUDRIQEV, Replimune is raising $150 million. The offering prices at $12.06 per share, a slight premium to the last reported sale price of $12.06 on August 7, 2026, and includes pre-funded warrants for certain investors. Net proceeds of approximately $140.5 million will fund the commercial launch and further pipeline development. The timing is strategic — the company had a going concern warning and cash only into Q1 2027, so this raise extends the runway significantly. However, the offering adds roughly 13.4 million shares (including pre-funded warrant shares), representing immediate dilution of about 13% to existing holders. The deal was upsized from the $150 million target announced earlier today, with strong demand allowing pricing at a premium — a positive signal given the company's recent regulatory success.
At the time of this filing, REPL was trading at $12.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.50 to $13.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.